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Chronic rheumatic heart disease. 
Combined defect of the mitral and tricuspid valve, 
combined mitral defect with
stenosis predominance.
Heart Failure II-B stage, IV FC. Permanent atrial 
fibrillation, tachysystolic form.
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Neglected disease of poverty
• Rheumatic heart disease is often missed in its early 
stages. It begins with a common throat infection 
caused by streptococcus bacteria (strep throat), which 
in some children sets off an abnormal immune 
reaction that damages heart valves. This reaction, 
called rheumatic fever, has symptoms that are vague 
and easily confused with other conditions. 
• People affected often look and feel healthy again once 
their outward symptoms are resolved, but with further 
streptococcal infections the rheumatic fever returns, 
worsening their heart damage. Often rheumatic heart 
disease is only detected when it is so advanced that 
only expensive and complicated heart surgery can save 
the person's life.
http://eurheartj.oxfordjournals.org
http://www.medclub.ru
Pathological anatomy
https://www.world-heart-federation.org
Cardiac dysfunction
https://www.world-heart-federation.org
Global advocacy
www.world-heart-federation.org/rhd
http://www.who.int/cardiovascular_diseases
http://www.escardio.org
http://www.cardiosource.org/acc
http://www.heart.org
World Heart Federation (Congress 2012):
Rheumatic heart disease affects children and young people living in conditions of 
poverty, poor sanitation and overcrowding. Practically eliminated in wealthy countries, it 
is still common in Africa, Asia and the Pacific. Over 15 million people around the 
world suffer from the condition, which kills 350 000 people a year and is the most 
common acquired heart disease found among children and young people in developing 
countries.
https://www.world-heart-federation.org
Online Rheumatic Heart Disease Network (RHDnet)
RHDnet is a public health resource developed by the World Heart Federation to support 
rheumatic heart disease control around the world. The site contains resources for health 
professionals including best practice tools (sample databases, management guidelines, 
and staff training resources) as well as links to other programme resources. RHDnet is the 
first dedicated, global network that attempts to connect and support clinicians and others 
interested in ARF and RHD control. A members' discussion forum has also been 
developed to link clinicians and specialists around the world and facilitate communication 
on various aspects of rheumatic fever and rheumatic heart disease control including 
secondary prophylaxis, the use of echocardiography and issues around cardiac surgery. A 
section has also been developed for interested members of the community.
Patient profile
• 75 years old (28.01.1937).
• Retired.
• Lives in a village.
• Urgent admission on 20.10.12
to ICU CCH UZ.
• Was transferred to the first cardiological
department at CCH UZ on 23.10.2012.
Complaints
Main:
•Pressure-like pain in the heart region when laying down on the back or left 
side without irradiation.
•Periodical feeling of a heart beat disruption.
Complaints disappear within 20-30 minutes when seated (excess oedema
on the lower extremities is noted)  or within an hour when laying down on 
the right side.
•Oedema of the lower extremities go off after administration of diuretics 
(veroshpiron).
•Constant shortness of breath at rest, aggravated by low physical activity 
and talking.
•Unsteadiness when walking and mild exercise.
•Constant noise in the ears.
•Cold extremities.
Additional:
•Pain in the left shoulder (applies diklak 5% cream).
•Pain in the large joints (elbows, knees) depending on the weather change.
Medical history
• During WWII suffered angina and acute arthritis, the treatment was not pursueded. Was 
sent to MLEC evaluation, however the disability group declined.
• In 1959 (after the birth of her daughter) was diagnosed with valvular mitral valve.
• In 1998, for the first time mentioned the increase in blood pressure to the level of 
140/90 mmHg
• Since 1998, 1-2 times a year is hospitalized in a hospital for a planned treatment in the 
cardiology department (Diagnosis: CHD: cardiosclerosis. Chronic rheumatic heart 
disease. A combined defect of the mitral valve. Arterial hypertension stage II, I stage of 
severity. CH II-B stage FC IV).
• Thrice was admitted to the ICU due to a sharp increase in complaints during physical or 
emotional stress.
• Last admission in June 2012, was discharged with the current diagnosis. 18/10/2012 at 
night had chocking episode, which was unsuccessfully treated with karvaltab. By the 
morning the complaints dissappeared.
• 10/20/2012 had another chocking episode, after which was hospitalized to the ICU CDB 
number 5.
History of life
• Was born in a full family, developed according to age.
• Diabetes, tuberculosis, malaria, viral hepatitis, sexually transmitted diseases 
and AIDS denies.
• In 1970 - hysterectomy with appendages.
• 1980 - TBI. After the trauma complained of constant noise in the ears.
• 2010 - The in-hospital pneumonia during routine treatment of the underlying 
disease.
• Heredity: father died at age 82 of heart failure, his mother at age of 73 -
cancer of the colon.
• Allergic history: notes the presence of allergy to one of the cardiovascular 
drugs prescribed by the attending physician at the hospital. The allergy was 
treated with antihistamines (loratadine, Claritin).
• Do not smoke. Does not consume alcohol.
Objective state-1:
• Moderate state, consciousness is clear, active.
• Normal constitution, weight 60 kg, height 157 cm, BMI = 
24.3.
• Pronounced cyanosis of the lips, tongue clean, damp.
• The thyroid gland is not clearly defined.
• Peripheral lymph nodes are not enlarged
• Pale skin, acrocyanosis.
• Gray hair at age of 40.
• Musculoskeletal system is normal. Soreness in paravertebral 
points in the cervical and thoracic regions. Moderate edema 
of both legs.
• Ripple on the legs on the back of the foot is reduced, trophic 
disorders of the skin of the lower extremities.
Objective state-2:
• Respiratory system: The chest of the normal form, the thoracic type of 
breathing, RR - 20 times / min. Palpation: voice trembling is moderate, 
equally balanced over the areas of the chest. Percussion: clear lung sounds. 
Auscultation: breathing is hard, no additional noise.
• Cardiovascular system: Palpation: The apical impulse is weakened. 
Percussion: heart enlarged to the top right. Auscultation: cardiac arrhythmic 
activity. First tone at the apex is reinforced, diastolic murmur, the murmor
growth when patient is in horizontal position laying on a left side. The 
emphasis of the second tone on the pulmonary artery. Heart rate - 94 beats / 
min, blood pressure - 110/70 mm. Hg. Art.
• Gastrointestinal system: stomach is soft, painless, no discrepancies of the 
abdominal muscles, the left and right part of the abdomen are symmetrical. 
No visible peristalsis. Scar in the suprapubic area, 4 cm above the 
symphysis pubis length of 10-12 cm Liver palpation smooth, painless, 
stands out costal 1.5 cm spleen and pancreas are not palpable.
• Urinary system: no change.
Minimal necessary examination
• Complete blood test, urine test
• Biochemical blood test (total protein, total bilirubin, AST, ALT, 
glucose, creatinine, creatine kinase MB, urea, creatine, asl-o, CRP)
• ECG dynamics
• Cardiac ultrasound and Doppler
Additional research methods
• Ultrasonography of the abdomen
• X-ray of the left shoulder joint (at the time of supervision was not 
met)
• Radiography of cervical spine (no)
General blood test
index Units of 
measureme
nt
Result Norm
erythrocytes Mlns/mkm 4,4 4.3-6.2
Hemoglobin g/l 126 120-140
color index 0,85 -1,15
ESR Mm/h 19 2-15
Thrombocytes g/l 147 180-320
Leukocytes 103/mkl 4,2 4,0 – 9,0
Eosinophils % - 1-5
stab % 6 > 5
segmented % 70 45-70
lymphocytes % 18 25-40
monocytes % 6 4-10
Conlcusion: thrombocytopenia, increased ESR
General urine test
index Units of 
measurement
Result Norm
density Kk/m3 1,018 1,015-1,025
рН 5,5 5,0-7,0
Protein g/l 0,056 -
Sugar Moll/l нет -
Leukocytes 1-3 1-2
color Stramineous Stramineous
Conclusion: proteinuria
Biochemical blood test
index Units of 
measurement
Result Norm
total protein g/l 68 65-85
total bilirubin Mkmoll/l 21,5 3-19
AsAt U/l 16 31
AlAt U/l 27 31
Glucose Mkmoll/l 9,9 3,9-6,4
Creatinine Mkmoll/l 103 53-97
Creatinekinase MB U/l 30 0-24
Urea mmoll/l 7,1 2,6-6,7
creatine phosphokinase U/l 112 24-170
Asl-O Not performed
CRP Not performed
Conclusion: hyperbilirubinemia, hyperglycemia, increased levels of  creatinine, 
creatine kinase MB, and urea
ECG 18.06.2012
Atrial fibrillation, tachysystolic form, isoelectric axis deviation to the right, signs of left 
ventricular hypertrophy, Ventricular rate- 98 beats / min
ECG 27.07.2012
Isoelectric axis deviation to the right, signs of left ventricular hypertrophy, Ventricular rate –
80 beats/min
Echocardiography
Conclusion:
Mitral stenosis 1 cm2. Calcification of the mitral valve.
Mitral regurgitation II degree.
Dilatation of the right heart and the left atrium.
Tricuspid regurgitation III degree.
* These data correspond to severe mitral stenosis
*М.Фрид, С.Грайнс "Кардиология" (пер. с англ.), 1996
Ultrasonography of the abdomen
Conclusion:
Diffuse changes in the liver and pancreas.
Non-significant ascites. 
Hepatosplenomegaly.
Basic clinical syndromes
• Valvular syndrome
• Congestive heart failure
• Atrial fibrillation
• Hepatosplenomegaly
• Diabetes mellitus
• Chronic kidney disease
• Articular syndrome
• Uric syndrome
HRB heart to ICD-10
• I05-I09 Chronic rheumatic heart disease
• I05 Rheumatic mitral valve disease. Included: the state, classified in the 
following categories I05.0 and I05.2-I05.9, sophisticated or refined as 
rheumatic excluded: cases updated as nonrheumatic (I34. -)
• I06 Rheumatic aortic valve disease. Excluded: cases unspecified as 
rheumatic (I35. -)
• I07 Rheumatic tricuspid valve disease. Included: cases updated or 
refined as rheumatic excluded: cases updated as nonrheumatic (I36. -)
• I08 lesions of multiple valves. Included: cases updated or refined as 
rheumatic Excluded: endocarditis, the valve is not specified (I38) 
Rheumatic diseases of endocardium, valve is not specified (I09.1)
• I08.1 combined lesions of mitral and tricuspid valves
• I09 Other rheumatic heart disease
Heart failure
Stages clinical signs
I Primary, latent, manifests only during exercise in the form of shortness of breath, tachycardia,
excessive fatigue. At rest, hemodynamics and function of organs is not impaired; reduced work
capacity
II Signs of hemodynamic instability. Disorder in metabolism and function of other organs
IIA Failure of the right or the left heart. Stagnation and dysfunction of other organs mostly appear
by the end of the working day (disappear after a night of rest)
IIБ The failure of the right or left heart. Stagnation of blood are more pronounced and appear at
rest (do not disappear after a night's rest, may be slightly reduced)
III Final, CH dystrophy with severe hemodynamic persistent violations of metabolism and function
of all organs, the development of irreversible changes in the structure of organs and tissues,
disability
Clinical stage heart failure (by NDStrazhesko and V.H.Vasilenko)
Heart failure
FC Clinical signs
I Patients with cardiac disease whose ordinary physical activity does not cause shortness of
breath, fatigue or palpitations
II Patients with cardiac disease and mild limitation of physical activity. Shortness of breath,
fatigue and palpitations apper during normal physical activity
III Patients with cardiac disease and severe limitation of physical activity. No complaints at rest,
but even minor physical activity cause dyspnea, fatigue, palpitations
IV Patients with heart disease which experience described above symptoms during any type of
physical activity and at rest
Functional class of heart failure (according to the criteria of the New York Heart Association - NYHA)
Atrial fibrillation
underlying disease ALFA, 
1999, (756 
participants)
AFASAK*, 1997, 
(677 participants)
CARAF**, 
2001, (899 
participants)
Arterial hypertension 39,4 41,8 39,4
Valvular degect 15,2 14,5 14,8
СН (NYHA, II-IV ФК) 50,0 68,2 17,6
IHD and AMI 16,6 24,7 42,0
cardiomyopathy 15,2 - -
COPD 11,2 - -
thyrotoxicosis 3,1 2,5 2,9
Diabetis 10,7 13,2 9,0
Isolated AF 29,3 - -
* - chronic AF;  ** - first time AF
Godtfredsen, 2002 г.
Atrial fibrillation
(evaluation forms)
Type Description
First time diagnosed First time diagnosed AF, regardless of the duration of 
arrhythmia or the nature of the course and severity of 
the symptoms of AF
paroxysmal Arrhythmias stop independently, without external 
interference, last for no more than 48 hours
persistent AF episodes that last more than 7 days and require 
medical correction
long-term persistent Persists for more than a year on the moment of a 
decision of cardiac correction
Permanent The patient and the doctor noted the permanent 
AF
Четвертый Национальный конгресс кардиологов Украины, 2000 г.
Atrial fibrillation (EHRA)
Class EHRA manifestations
I No symptoms
II Mild symptoms, normal daily activities are 
not affected
III Severe symptoms, changed daily activities
IV Disabling symptoms, normal daily activities 
can not be performed
European Heart Rhythm Association, 2010
Atrial fibrillation (HR)
Form HR
Normosystolic 60-89 bpm
Bradysistolyc < 60 bpm
Tachysystolic > 90 bpm
CKD. criteria for diagnosis
Stage Characteristic GF
(ml/ьшт/1,73m2)
Creatinine
(mkmol/l)
I CKD with normal or elevated GF >90 <123
II CKD with chronic renal failure 
with a moderate or low GF
60-89 123-176
III ХCKD with chronic renal failure, 
with an average decrease in GF
30-59 177- 352
IV CKD with chronic renal failure in 
patients with severe decrease in 
GF
15-29 353-528
V CKD with terminal renal failure <15 >528
Рекомендации общества нефрологов Украины, 2005
Clinical diagnosis
• Chronic rheumatic heart disease. Combined mitral and 
tricuscipid valve defects, combined mitral  defect with stenosis 
predominance.
• HF II-B stage, IV FC.
• Permanent atrial fibrillation, tachysystolic form.
• CKD stage III
• Type 2 diabetes
• Chronic arthritis (shoulder joint?)
• Osteochondrosis of the cervical spine?
Recommendations for further examination
• lipidogram
• Daily glycemic profile, HbA1c
• BP control
• Ophthalmologist consultation
• Radiography of the left shoulder and cervical 
spine
• Biochemical blood test: CRP, asl-o.
Drug treatment (assigned in the hospital)
Veroshpiron (Spironolactone) - 50 mg per day
Bisoprolol (Bisoprolol) - 5 mg 1 time a day
Cardiomagnil (acetylsalicylic acid + magnesium
hydroxide) - 75 mg 1 time per day
Lozap (Losartan) - 12,5 mg 1 time a day
Diklak-gel 5% (Diclofenac) - applied to the skin 
around the painful joint
Assessing the risks
In the age over 70 years, heart failure worsens the prognosis and 
outcome of surgery.
Unreasonably prolonged therapeutic management of patients with 
mitral heart disease leads to the progression of malformations and 
heart failure, which in turn reduces the tolerance to surgery. 
Postoperative mortality in this group was 37,1% (NYHA).
Факторы риска и оптимизация отбора на хирургическое лечение больных с 
митральными пороками сердца, 2005. Старжевская, Л.Е.
Given the age, history and comorbidities, 
the patient may be attributed to a group 
of risk - from surgical treatment refused.
Recommendations for treatment of the 
patient
1. Anticoagulants (vitamin K antagonists and 
aspirin) in patients with persistent atrial 
fibrillation, thromboembolic events in history, 
with mitral stenosis and prosthetic heart valves. 
Mandatory monitoring of INR - international 
normalized ration (PT).
2. Treatment of heart failure, according to its type.
3. Treatment of type 2 diabetes (diet).
«Серцево-судинні захворювання. Класифікація, стандарти діагностики та 
лікування кардіологічних хворих» а ред. проф. В. М. Коваленка, 2007
Recommendations for treatment of the 
patient
Recommendations for treatment of the 
patient

The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 
Guidelines for the management of atrial fibrillation. 
Recommendations for treatment of the 
patient
• Warfarin - one of the most effective drugs for the treatment of atrial fibrillation 
and stroke prevention. However, a significant disadvantage of this tool is in the 
necessasaty of regular blood tests aimed to adjust the dosage of the drug. 
Wrong dose of warfarin can significantly reduce its effectiveness and might not 
lead to a desired result.
• Dabigatran, Rivaroxaban – alternatives to warfarin. These medications reduce 
the risk of stroke in patients with atrial fibrillation with a clinically significant 
reduction in the risk bleeding for 35 - 75%.
Recommendations for treatment of the 
patient
Corrections to the treatment. Drug-free 
treatment
• Control of physcial
activity: reduction of 
physical activity is 
recommended;
• Diet: the restriction or 
withdrawal of food 
containing animal fats and 
rapidly absorbed 
carbohydrates, as well as 
limiting salt intake and 
salt-containing products.
Corrections to the treatment. Conservative 
treatment
Furosemide (prescribed in CKD III) - 40 mg in the morning 
before the disappearance of edema
Lozap 12.5 mg once a day (followed by titration)
Bisoprolol - 5 mg once a day (followed by titration)
Cardiomagnil- 75 mg once a day
Warfarin - starting dose is 5 mg per day at the same time 
(with subsequent titration and control of INR 4 days after 
treatment)
Diklak Gel 5% - applied to skin around the painful joint
Thank you for your 
attention!
